All In Biotech

NDA 201699 · Cubist Pharms LLC

Dificid

Fidaxomicin · Oral · Macrolide Antibacterial

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: May 28, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

May 27, 2011

Approved uses

3

Original approval plus efficacy supplements

Registered trials

33

13 Phase 3, 3 recruiting

FAERS reports

2,417

1,442 serious, 258 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 16, 2024.

DIFICID is a macrolide antibacterial indicated in adult and pediatric patients 6 months of age and older for the treatment of C. difficile -associated diarrhea. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile . ( 1.2 ) 1.1 Clostridioides difficile -Associated Diarrhea DIFICID ® is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile -associated diarrhea (CDAD). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile . When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Fidaxomicin is an antibacterial drug [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 24, 2020 Supplement 12 · Efficacy · priority review OrphanLetterLabel
  • Feb 24, 2015 Supplement 9 · Efficacy · priority review Letter
  • May 27, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewPediatric Written Request
1 products under this application
  • DIFICID · FIDAXOMICIN 200MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fidaxomicin" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • clostridium difficile infection484
  • drug ineffective419
  • diarrhoea354
  • disease recurrence179
  • clostridium difficile colitis162
  • off label use135
  • nausea125
  • treatment failure120
  • abdominal pain88
  • no adverse event86
  • pyrexia78
  • vomiting73

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201115
201236
2013276
2014122
2015162
2016121
201799
2018147
2019195
2020192
2021156
2022170
2023160
2024206
2025220
2026140

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dificid (Fidaxomicin)

2024 spending

$154M

Beneficiaries

26,020

34,589 claims

Per beneficiary

$5,909

$245.75 per unit

View as table
YearSpending
2020$47,384,305
2021$67,952,402
2022$103,081,747
2023$127,162,103
2024$153,755,014

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 78 on PubMed

Sponsor: Cubist Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.